Treos Bio

About Treos Bio

Treos Bio, founded in 2013, is a clinical-stage biotechnology company headquartered in London, operating at the intersection of computational data science and cancer immunotherapy. The firm was established by John Hautman, an attorney and entrepreneur with over 35 years of experience in advising technology companies, and Dr. Julianna Lisziewicz. The company's core mission is to address the dual challenges of patient and tumor heterogeneity in cancer treatment.

Treos Bio is developing a new generation of off-the-shelf peptide immunotherapies that are digitally matched to a patient's genetics. This approach utilizes computational platforms and proprietary biomarkers to create treatments that stimulate effective, cancer-specific immune responses. A key differentiator is that their process does not require a tumor biopsy. The company's technology, centered around "Promiscuous Epitopes" (PEPIs), involves small protein fragments that bind to multiple MHC molecules, triggering strong immune responses against tumor antigens. This method aims to turn immunologically "cold" tumors into "hot" ones, making them more susceptible to treatment.

The business model focuses on the development and clinical validation of its proprietary cancer vaccines and companion diagnostics. Revenue generation will likely stem from partnerships, licensing agreements, and the eventual commercialization of their therapeutic products. The company serves the oncology market, providing potential solutions for healthcare providers treating various cancers. Their product pipeline includes both off-the-shelf and personalized immunotherapies. The lead product candidate, PolyPEPI1018, is an off-the-shelf immunotherapy for colorectal cancer that has undergone multiple clinical trials. Treos is also developing a PEPI Panel, a library of 3,286 immunogenic peptide fragments for 19 cancer indications, allowing for the rapid formulation of personalized treatments. The company has secured significant funding to advance its clinical trials, including an $8 million round in 2017 and a $14 million Series B in 2021.